Research focuses on the design of a multi-epitope polyvalent vaccine against Human Respiratory Syncytial Virus (RSV), a leading cause of lower respiratory tract infections. The study utilizes computational methods and immunoinformatics tools to predict potential vaccine candidates and their interactions with Toll-like receptors (TLRs).
Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to
March 14, 2024